AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters

AstraZeneca Plc's  (NASDAQ: AZN ) COVID-19 antibody cocktail has been cleared for use in a medical tourism zone in China's southern province of Hainan, Reuters reported  citing local media. The report mentioned that China allows early use of new medical products in the special zone in Qionghai city due to several preferential policies granted to ... Full story available on Benzinga.com